Discovery Europe
Join and network with over 450 industry discovery biology and chemistry leaders at the renowned Drug Discovery Summit in Basel, where they address critical strategies in target identification, validation and HIT optimisation of small and large molecule drugs.
Join and network with over 450 industry discovery biology and chemistry leaders at the renowned Drug Discovery Summit in Basel, where they address critical strategies in target identification, validation and HIT optimisation of small and large molecule drugs.
We are sponsors at this event!
Come and visit our team at our booth at #13 and meet our team to discuss how bit.bio offers partnering opportunities that affords access to the most relevant parental human cell types and corresponding disease models. These models are physiologically relevant and highly characterised, offering predictive, in vitro, human cells for early drug discovery, phenotypic screening, and high-content imaging applications.
Dominic Hussey, Senior Director, Sales will be a panelist on ’Genomic and Genetic data for target ID and validation” and will be joined by Davide Gianni, Senior Director, AstraZeneca and Ulrike Kunzel, Associate Principal Scientist, AstraZeneca.
Dr Malika, Bsibsi, Research Leader, Charles River Laboratories is our speaker in our talk on “Advancing neurodegenerative disease drug discovery through innovative human iPSC-derived cell-based assays” where she will discuss:
- Human iPSC-derived microglia and neurons for better drug screening in neurodegenerative diseases
- A co-culture cell model of neurons and astrocytes to predict in vivo neurotoxicity of ASO drug candidates
- bit.bio’s ioCRISPR-Ready Cells™ improving the consistency and scalability of human cells in functional genomics
- CRISPR screens using glutamatergic neurons and microglia identifying crucial genes for neurodegeneration.